Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform, Sentia, in Canada
  • Sentia analyses sulfur dioxide in post-fermentation red or white wine
  • The agreement is for three years and includes standard renewal and termination options
  • On the market, UBI is up 1.96 per cent and is trading at 52 cents per share

Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform device, Sentia, in Canada.

Vines to Vintages is an independent wine laboratory performing analysis for wineries in Canada and United States. It also sells winemaking supplies and equipment.

Sentia analyses sulfur dioxide in post-fermentation red or white wine. The product is then able to display, through a touchscreen, the test results in under a minute.

Sulfur dioxide is added in the winemaking process to protect the wine from oxidation and bacterial spoilage.

The agreement is for three years and includes standard renewal and termination options.

UBI CEO John Sharman said this is another positive step in the commercialisation of Sentia globally.

“Vines to Vintages is well represented in all of Canada’s wine regions and has access to 700 wineries. The deal includes an initial commitment to purchase
Sentia devices and strips which will be delivered over the course of the next few weeks,” he said.

“We believe the possibility of Sentia’s future testing capability for Glucose,
Fructose, Malic Acid and others will add significant value to the winemaking industry,” he added.

UBI is currently negotiating terms with a number of key industry players around the world and looks forward to reporting additional distribution partnerships in the future.

On the market, UBI is up 1.96 per cent and is trading at 52 cents per share at 2:49 pm AEDT.

UBI by the numbers
More From The Market Herald

" Monash IVF Group (ASX:MVF) suspends certain procedures in Victoria

Following new health orders in Victoria, Monash IVF Group (ASX:MVF) says non-urgent surgery protocols will disrupt…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) suspends non-urgent elective surgeries in NSW & VIC

Virtus Health (ASX:VRT) has suspended all non-urgent elective surgeries in NSW and Victoria as the State…
Oneview HealthCare (ASX:ONE) - CEO, James Fitter

" Oneview Healthcare (ASX:ONE) has first-ever operating cash inflow

Oneview Healthcare (ASX:ONE) has reported a net operating cash inflow for the first time in its…
Amplia Therapeutics - CEO and MD, Dr John Lambert

" Amplia Therapeutics (ASX:ATX) set for AMP945 drug trials

Amplia Therapeutics (ASX:ATX) completes manufacture of its clinical-stage drug candidate ahead of planned trials.